Home/Filings/4/0001123292-20-000665
4//SEC Filing

KDev Investments AB 4

Accession 0001123292-20-000665

CIK 0001781983other

Filed

Apr 14, 8:00 PM ET

Accepted

Apr 15, 9:18 AM ET

Size

8.8 KB

Accession

0001123292-20-000665

Insider Transaction Report

Form 4
Period: 2020-04-13
Transactions
  • Sale

    Common Stock

    2020-04-13$31.25/sh210,548$6,579,6252,234,289 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2020-04-13$31.25/sh210,548$6,579,6252,234,289 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2020-04-13$31.25/sh210,548$6,579,6252,234,289 total(indirect: See Footnote)
Footnotes (2)
  • [F1]The amount of securities of Aprea Therapeutics, Inc. (the "Issuer") reported as beneficially owned includes shares held of record by: KDev Investments AB, Karolinska Development AB and KCIF Co-Investment Fund KB (collectively, the "Reporting Persons").
  • [F2]Karolinska Development AB ("Karolinska") is the majority owner and co-manager of KDev Investments AB and a limited partner of KCIF Co-Investment Fund KB. Karolinska and each of the other Reporting Persons disclaim beneficial ownership of any shares of the Issuer's Common Stock owned of record by any of the other Reporting Persons except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that any such entity is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The address of each of (i) KDev Investments AB, (ii) Karolinska Development AB, and (iii) KCIF Co-Investment Fund KB is Tomtebodavagen 23A, SE 171 65 Solna, Sweden.

Issuer

Aprea Therapeutics, Inc.

CIK 0001781983

Entity typeother
IncorporatedSweden

Related Parties

1
  • filerCIK 0001789888

Filing Metadata

Form type
4
Filed
Apr 14, 8:00 PM ET
Accepted
Apr 15, 9:18 AM ET
Size
8.8 KB